AstraZeneca plc (AZN) PT Set at GBX 4,700 by Morgan Stanley

AstraZeneca plc (LON:AZN) has been given a GBX 4,700 ($62.45) price objective by investment analysts at Morgan Stanley in a report issued on Friday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target points to a potential downside of 8.95% from the company’s current price.

Several other research firms have also recently weighed in on AZN. UBS AG set a GBX 5,150 ($68.43) target price on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Kepler Capital Markets restated a “buy” rating and set a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Liberum Capital restated a “buy” rating and set a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 5,172.64 ($68.73).

Shares of AstraZeneca plc (AZN) opened at 5162.00 on Friday. The stock’s market capitalization is GBX 65.35 billion. The firm’s 50 day moving average is GBX 4,923.51 and its 200 day moving average is GBX 4,914.37. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

WARNING: “AstraZeneca plc (AZN) PT Set at GBX 4,700 by Morgan Stanley” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://ledgergazette.com/2017/10/22/astrazeneca-plc-azn-pt-set-at-gbx-4700-by-morgan-stanley.html.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of t

Several other research firms have also recently weighed in on AZN. UBS AG set a GBX 5,150 ($68.43) target price on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Kepler Capital Markets restated a “buy” rating and set a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Liberum Capital restated a “buy” rating and set a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 5,172.64 ($68.73).

Shares of AstraZeneca plc (AZN) opened at 5162.00 on Friday. The stock’s market capitalization is GBX 65.35 billion. The firm’s 50 day moving average is GBX 4,923.51 and its 200 day moving average is GBX 4,914.37. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

WARNING: “AstraZeneca plc (AZN) PT Set at GBX 4,700 by Morgan Stanley” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://ledgergazette.com/2017/10/22/astrazeneca-plc-azn-pt-set-at-gbx-4700-by-morgan-stanley.html.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply